---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-031458"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:43:17.531283+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharmaceuticals terminates CVRs from prior spin-off; no financial impact

## Summary
- CVRs originated from 2021 sale of Cellect Biotherapeutics to EnCellX; Quoin not entitled to proceeds.
- Termination certified by EnCellX CEO on Feb 29, 2024; CVRs had no asset or liability recorded.
- CVR termination has no financial impact on Quoin; no carrying value on balance sheet.

## SEC filing metadata
- accession: 0001104659-24-031458
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465924031458/0001104659-24-031458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465924031458/tm248148d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-031458
- JSON: https://secwatch.observer/filing/0001104659-24-031458.json
- Plain text: https://secwatch.observer/filing/0001104659-24-031458.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.